NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKGN NKGEN BIOTECH INC

Not Yet Opened 12-20 16:00:00 EST

0.6400

+0.0749

+13.25%

盘后0.6400

+0.00000.00%

19:59 EST

High0.6547	Low0.5558	Vol443.15K
Open0.5840	D1 Closing0.5651	Amplitude17.50%
Mkt Cap22.63M	Tradable Cap10.31M	Total Shares35.36M
T/O266.66K	T/O Rate2.75%	Tradable Shares16.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NKGN","market":"US","secType":"STK","nameCN":"NKGEN BIOTECH INC","latestPrice":0.64,"timestamp":1734728400000,"preClose":0.5651,"halted":0,"volume":443146,"hourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.64,"latestTime":"19:59 EST","volume":18086,"amount":11667.1526,"timestamp":1734742740101},"delay":0,"floatShares":16114200,"shares":35362376,"eps":-4.347381,"marketStatus":"Not Yet Opened","change":0.0749,"latestTime":"12-20 16:00:00 EST","open":0.584,"high":0.6547,"low":0.5558,"amount":266663.1055,"amplitude":0.175013,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.347381,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":0.5651,"preHourTrading":{"tag":"盘前","latestPrice":0.56,"preClose":0.5651,"latestTime":"09:25 EST","volume":7331,"amount":3985.997831,"timestamp":1734704700025},"postHourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.64,"latestTime":"19:59 EST","volume":18086,"amount":11667.1526,"timestamp":1734742740101},"volumeRatio":1.0885400698466592},"requestUrl":"/m/hq/s/NKGN/tweets","defaultTab":"tweets","newsList":[{"id":"2488986311","title":"BRIEF-Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488986311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488986311?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:16","pubTimestamp":1733174164,"startTime":"0","endTime":"0","summary":"BRIEF-Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.Dec 2 (Reuters) - Nkgen Biotech Inc NKGN.O:NKGEN BIOTECH: SELECTED AS PREFERRED STALKING HORSE BIDDER FOR NKMAX CO., IN NKM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N30W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2488986893","title":"NKGen Biotech: Selected as Preferred Stalking Horse Bidder for Nkmax Co., in Nkmax's Court-Managed Rehabilitation Process in South Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2488986893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488986893?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:14","pubTimestamp":1733174089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N30W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2488968748","title":"NKGen Biotech Selected as Stalking Horse Bidder for NKMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968748","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488968748?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:05","pubTimestamp":1733173500,"startTime":"0","endTime":"0","summary":"Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer  cell therapy is already legal.NKGen proposal included up to $18 million in committed funding.“As we have made tremendous progress in our clinical program especially with the launch of our phase II trial for moderate stage Alzheimer’s disease, we felt that it was essential for us to preserve the very close scientific and clinical partnership with the NKMax team, rather than have NKMax acquired by someone without any cell therapy knowledge or experience”, commented Paul Y. Song, MD, Chairman and CEO of NKGen Biotech. “As we continue to work towards US FDA approval, we will be able to begin to commercialize troculeucel in countries like Japan, Thailand, Malaysia, Mexico and others where an autologous non-genetically modified cell therapy is considered as a legal treatment and already readily available. W","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GWvn3FS6iClU6MjzVvwGnA--~B/aD0xMjA7dz0zODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/982030109771eb306c2a7df2ab73f4e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GWvn3FS6iClU6MjzVvwGnA--~B/aD0xMjA7dz0zODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/982030109771eb306c2a7df2ab73f4e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-selected-stalking-horse-210500152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGNW","NKGN"],"gpt_icon":0},{"id":"2486054832","title":"NKGen Biotech gets Nasdaq notice related to delayed quarterly report","url":"https://stock-news.laohu8.com/highlight/detail?id=2486054832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486054832?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:30","pubTimestamp":1732656620,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced it received a notice on November 20 rom the Listing Qualifications Department of The Nasdaq Stock Market stating tha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-gets-nasdaq-notice-related-to-delayed-quarterly-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-gets-nasdaq-notice-related-to-delayed-quarterly-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2095319765.USD","NDAQ","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NKGN","LU2210150020.SGD","BK4588","BK4112","PSQ","SQQQ","MNQmain","BK4139","NQmain","LU2210149790.SGD","IE00B64PRP62.GBP","TQQQ","QID","IE00BGHQF748.EUR","QLD",".IXIC"],"gpt_icon":0},{"id":"2486536834","title":"NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2486536834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486536834?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:15","pubTimestamp":1732655700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUAQWTWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","NKGN","LU2095319765.USD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","NKGNW","BK4588"],"gpt_icon":0},{"id":"2483829067","title":"BRIEF-Nkgen Biotech Inc  On Nov 5, As Part Of Cost-Reduction Efforts, Conducted A Group Layoff Of 16 Employees.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483829067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483829067?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:33","pubTimestamp":1731454400,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Nkgen Biotech Inc   :   * NKGEN BIOTECH INC:  ON NOV 5, AS PART OF \\GREATER COST-REDUCTION EFFORTS, CONDUCTED A GROUP LAYOFF OF 16 EMPLOYEES.Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2483066798","title":"NKGen Biotech Inc:  on Nov 5, as Part of \\Greater Cost-Reduction Efforts, Conducted a Group Layoff of 16 Employees.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066798?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:30","pubTimestamp":1731450638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2479762939","title":"BRIEF-Nkgen Biotech Says Co Placed 19 Employees On Furlough","url":"https://stock-news.laohu8.com/highlight/detail?id=2479762939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479762939?lang=en_us&edition=fundamental","pubTime":"2024-10-31 06:04","pubTimestamp":1730325843,"startTime":"0","endTime":"0","summary":"Oct 30  - Nkgen Biotech Inc   :   * NKGEN BIOTECH INC - ON OCT 24, CO PLACED 19 EMPLOYEES ON FURLOUGH, EFFECTIVE OCTOBER 27   * NKGEN BIOTECH INC - PLANS FOR FURLOUGH TO LAST FROM OCTOBER 27 THROUGH NOVEMBER 9   * NKGEN BIOTECH - CO'S INABILITY TO PAY ITS PAYROLL OBLIGATIONS MAY RESULT IN EMPLOYEES TERMINATING RELATIONSHIP WITH CO AND/OR PURSUING LEGAL REMEDIESSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2479676183","title":"NKGen Biotech - Co's Inability to Pay Its Payroll Obligations May Result in Employees Terminating Relationship With Co and/or Pursuing Legal Remedies","url":"https://stock-news.laohu8.com/highlight/detail?id=2479676183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479676183?lang=en_us&edition=fundamental","pubTime":"2024-10-31 05:24","pubTimestamp":1730323478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61VH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2479176906","title":"NKGen Biotech Inc - on Oct 24, Co Placed 19 Employees on Furlough, Effective October 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2479176906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479176906?lang=en_us&edition=fundamental","pubTime":"2024-10-31 05:24","pubTimestamp":1730323478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M61VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2479140134","title":"NKGen Biotech announces presentation of two posters in AD","url":"https://stock-news.laohu8.com/highlight/detail?id=2479140134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479140134?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:31","pubTimestamp":1730205070,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced the presentation of two posters, on its first-in-kind, autologous, non-genetically modified NK cell product, trocule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-announces-presentation-of-two-posters-in-ad?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-announces-presentation-of-two-posters-in-ad?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2479952406","title":"NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479952406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479952406?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:05","pubTimestamp":1730203500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA3MVV2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2479409084","title":"NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479409084","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479409084?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:05","pubTimestamp":1730203500,"startTime":"0","endTime":"0","summary":"Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are detectable up to 10 years before dementia symptoms appear according to recent reports. This suggests a potential role for the use of troculeucel in delaying or preventing dementia onset in asymptomatic individuals with detectable biomarkers.“Despite the majority of subjects receiving suboptimal dosing and only four total doses in the Phase 1 pilot trial, we found that our autologous NK cell treatment was safe and that 90% of evaluable subjects experienced stable or improved cognitive function,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “We also revealed that several subjects demonstrated reductions in several neuroinflammation biomarkers, such as GFAP, NfL, p-tau181, GDF-15, and LTBP2. We believe that increased screening for these biomark","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M_wUcWvJTgUWEOx1p0v2RQ--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4d4a8720d597ce097de176741b8c8c1b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M_wUcWvJTgUWEOx1p0v2RQ--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4d4a8720d597ce097de176741b8c8c1b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-presents-phase-1-120500504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGN","NKGNW"],"gpt_icon":0},{"id":"2473472426","title":"NKGen Biotech Announces Poster Presentations at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2473472426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473472426?lang=en_us&edition=fundamental","pubTime":"2024-10-08 20:05","pubTimestamp":1728389100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nTUA8D7RZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2473242985","title":"NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2473242985","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473242985?lang=en_us&edition=fundamental","pubTime":"2024-10-08 20:05","pubTimestamp":1728389100,"startTime":"0","endTime":"0","summary":"SANTA ANA, Calif., Oct. 08, 2024  -- NKGen Biotech Inc.  , a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in subjects with Alzheimer’s disease, at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference  to be held in Madrid, Spain from October 29 – November 1, 2024.Treatment of Moderate Alzheimer’s Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells  with Enhanced Activity – Report of the Phase I results of the Phase I/IIa Study. Paul Y. Song, Lucia Hui, Hank Lee, Juan Mata, Katia Betito, Harry Chung, Jesse Carr. Poster Session 1 - Theme 02: Clinical Trials: Results. NKGen is a clinical-stage biotechnology company focused on the development an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M_wUcWvJTgUWEOx1p0v2RQ--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4d4a8720d597ce097de176741b8c8c1b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M_wUcWvJTgUWEOx1p0v2RQ--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4d4a8720d597ce097de176741b8c8c1b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-announces-poster-presentations-120500853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NKGNW","NKGN"],"gpt_icon":0},{"id":"2472274566","title":"BRIEF-Nkgen Biotech Size Of Board Temporarily Reduced From Five To Two Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2472274566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472274566?lang=en_us&edition=fundamental","pubTime":"2024-10-04 06:05","pubTimestamp":1727993109,"startTime":"0","endTime":"0","summary":"Oct 3 (Reuters) - Nkgen Biotech Inc   :   * NKGEN BIOTECH: SIZE OF BOARD TEMPORARILY REDUCED FROM FIVE TO TWO DIRECTORS   * NKGEN BIOTECH: SIZE OF EACH COMMITTEE IS TEMPORARILY REDUCED FROM THREE TO ONE MEMBERSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2472240946","title":"NKGen Biotech: Size of Each Committee Is Temporarily Reduced From Three to One Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2472240946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472240946?lang=en_us&edition=fundamental","pubTime":"2024-10-04 05:27","pubTimestamp":1727990842,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nFWN3LF143:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2470051356","title":"BRIEF-NKGen Biotech Receives Deficiency Letter From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2470051356","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470051356?lang=en_us&edition=fundamental","pubTime":"2024-09-28 04:12","pubTimestamp":1727467950,"startTime":"0","endTime":"0","summary":"Sept 27 (Reuters) - Nkgen Biotech Inc   :   * NKGEN BIOTECH INC -ON SEPT 23, GOT  DEFICIENCY LETTER FROM NASDAQ ON CO'S FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARDSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU2210149790.SGD","NKGN","LU1548497426.USD","LU0348723411.USD","BK4585","PSQ","LU0724618433.USD","LU2095319765.USD","BK4141","IE00BZ199S13.USD","LU1854104046.USD","ON","LU1861214812.USD","IE00B64PRP62.GBP","LU2357305700.SGD","NDAQ","BK4112","LU1720051017.SGD","LU1861220033.SGD","LU1854103824.USD","IE00B3QW5Z07.USD","BK4588","LU2298322129.HKD","LU0124384867.USD","IE00BGHQF748.EUR","SQQQ","LU2210150020.SGD","QLD",".IXIC","IE00BD6J9T35.USD","LU1861215975.USD","LU1861219969.SGD","MNQmain","LU1978683503.SGD","LU2360107325.USD","QID","NQmain","IE00BKPKM429.USD","TQQQ","BK4139","BK4512"],"gpt_icon":0},{"id":"2470059464","title":"NKGen Biotech Inc -on Sept 23, Got  Deficiency Letter From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard","url":"https://stock-news.laohu8.com/highlight/detail?id=2470059464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470059464?lang=en_us&edition=fundamental","pubTime":"2024-09-28 04:03","pubTimestamp":1727467411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240927:nFWN3L918W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2466327921","title":"NKGen Biotech Inc - No Drug-Related Adverse Reactions in Phase 1 Cohort After 3 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2466327921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466327921?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:05","pubTimestamp":1726142759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nTUA2VLC8T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkgenbiotech.com","stockEarnings":[{"period":"1week","weight":0.2805},{"period":"1month","weight":1.0447},{"period":"3month","weight":0.6576},{"period":"6month","weight":-0.4622},{"period":"1year","weight":-0.7739},{"period":"ytd","weight":-0.7673}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.14783},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.154196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.457766},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.062968},{"month":5,"riseRate":0.666667,"avgChangeRate":0.034541},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.076206},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.046734},{"month":8,"riseRate":0.25,"avgChangeRate":-0.070427},{"month":9,"riseRate":0.5,"avgChangeRate":-0.178831},{"month":10,"riseRate":0.5,"avgChangeRate":-0.226061},{"month":11,"riseRate":0.75,"avgChangeRate":0.158594},{"month":12,"riseRate":0.5,"avgChangeRate":0.099527}],"exchange":"NYSE","name":"NKGEN BIOTECH INC","nameEN":"NKGEN BIOTECH INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NKGEN BIOTECH INC(NKGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NKGEN BIOTECH INC,NKGN,NKGEN BIOTECH INC股票,NKGEN BIOTECH INC股票老虎,NKGEN BIOTECH INC股票老虎国际,NKGEN BIOTECH INC行情,NKGEN BIOTECH INC股票行情,NKGEN BIOTECH INC股价,NKGEN BIOTECH INC股市,NKGEN BIOTECH INC股票价格,NKGEN BIOTECH INC股票交易,NKGEN BIOTECH INC股票购买,NKGEN BIOTECH INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NKGEN BIOTECH INC(NKGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction